Friday, July 10, 2026
🇺🇸 FDA

Intelligence · INN directory

Immunology Drugs Directory

Autoimmune and immunology biologics — anti-TNF, IL inhibitors, JAK inhibitors, and immunology pipeline assets.

Drugs in segment 63
Companies 1,771
Pipeline programs 20,548

Quick answer

Immunology & autoimmune drugs: NovaPharmaNews indexes 63 pharmaceutical drugs in this therapeutic segment with regulatory status, pipeline programs, patents, and congress coverage cross-links. Autoimmune and immunology biologics — anti-TNF, IL inhibitors, JAK inhibitors, and immunology pipeline assets.

Recently updated

FDA-approved

63 drugs · Immunology & autoimmune drugs · by data quality · Page 1 of 3

  1. dupilumab

    DUPIXENT Sanofi-aventis Healthcare Pty Ltd

    INJECTION FDA: approved · EMA: approved · TGA: approved · PMDA: approved · NMPA: clinical trials

    D11AH05

  2. human igg1 monoclonal antibody specific for human interleukin-1 alpha

    HUMAN IGG1 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN INTERLEUKIN-1 ALPHA XBIOTECH XBiotech Germany GmbH

    EMA: refused

    L01

  3. lebrikizumab

    EBGLYSS S.A.

    EMA: approved · PMDA: approved

    D11AH10

  4. reslizumab

    CINQAERO Teva Pharma GmbH

    INJECTION FDA: approved · EMA: approved

    R03DX08

  5. rilonacept

    RILONACEPT FGK REPRESENTATIVE SERVICE GMBH Regeneron UK Limited

    SINGLE-USE FDA: approved · EMA: application withdrawn

    L04AC04

  6. tildrakizumab

    ILUMYA Lacuna Pharma Pty Ltd

    EMA: approved · TGA: approved

    L04AC

  7. abrocitinib

    CIBINQO

    ORAL FDA: approved · EMA: approved · PMDA: approved

    D11AH08

  8. anakinra

    KINERET Swedish Orphan Biovitrum Pty Ltd

    SUBCUTANEOUS FDA: approved · EMA: approved · TGA: approved

    L04AC03

  9. baricitinib

    OLUMIANT

    ORAL FDA: approved · EMA: approved · TGA: approved · PMDA: approved · NMPA: clinical trials

    L04AA37

  10. basiliximab

    SIMULECT

    SINGLE-USE FDA: approved · EMA: approved

    L04AC02

  11. benralizumab

    FASENRA PEN AstraZeneca

    INJECTION FDA: approved · EMA: approved · TGA: approved · PMDA: approved

    R03DX10

  12. bimekizumab-bkzx

    BIMZELX

    INJECTION FDA: approved

  13. brodalumab

    KYNTHEUM

    INJECTION FDA: approved · EMA: approved · PMDA: approved

    L04AC12

  14. canakinumab

    CANAKINUMAB NOVARTIS

    SUBCUTANEOUS FDA: approved · EMA: approved · PMDA: approved · NMPA: clinical trials

    L04AC08

  15. daclizumab

    ZENAPAX

    INJECTION FDA: approved · EMA: withdrawn

    L04AC01

  16. delgocitinib

    ANZUPGO

    TOPICAL FDA: approved · EMA: approved · PMDA: approved

    D11AH11

  17. deuruxolitinib phosphate

    LEQSELVI

    ORAL FDA: approved

  18. fedratinib hydrochloride

    INREBIC

    ORAL FDA: approved

  19. guselkumab

    TREMFYA Janssen-Cilag Pty Ltd

    INJECTION FDA: approved · EMA: approved · TGA: approved · PMDA: approved

    L04AC

  20. ixekizumab

    TALTZ

    INJECTION FDA: approved · EMA: approved · TGA: approved · PMDA: approved

    L04AC13

  21. lebrikizumab-lbkz

    EBGLYSS

    INJECTION FDA: approved

  22. mepolizumab

    NUCALA GlaxoSmithKline

    SUBCUTANEOUS FDA: approved · EMA: approved · TGA: approved · PMDA: approved

    R03DX09

  23. mirikizumab-mrkz

    OMVOH

    SUBCUTANEOUS FDA: approved

  24. nemolizumab-ilto

    NEMLUVIO

    INJECTION FDA: approved

Frequently asked questions

How many immunology & autoimmune drugs are in the directory?

63 drug profiles match this therapeutic area filter based on class, mechanism, target, and INN metadata.

How are drugs assigned to a therapeutic area?

Classification uses WHO therapeutic class, mechanism of action, molecular target, and INN pattern matching against curated oncology, metabolic, CNS, rare disease, and immunology taxonomies.

Where does regulatory data come from?

Profiles combine FDA Drugs@FDA, EMA EPAR references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.